Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions

Journal of the American College of Cardiology

Volumn 33, Issue 1, 1999, Pages 234-241

  Kaesemeyer, Wayne H ^a   Caldwell, Ruth B ^a   Huang, Jianzhong ^a   William Caldwell, R ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE SYNTHASE; PRAVASTATIN; SIMVASTATIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CATTLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; HEART INFARCTION; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CATTLE; CHOLESTEROL, LDL; CULTURE TECHNIQUES; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; MALE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PLATELET AGGREGATION; PRAVASTATIN; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION;

EID: 0032896636     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00514-2     Document Type: Article

References (37)

1. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 1995;92:2419-25.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
3. Lacoste L, Lam JYT. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients [abstract]. J Am Coll Cardiol 1996;27:413A.
4. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998;31:684-91.
5. Wilson TW, Alonso-Galicia M, Romas RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 1998;31:225-31.
6. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998;19:26-37.
7. Keh D, Gerlach M, Kürer I, et al. The effects of nitric oxide (NO) on platelet membrane receptor expression during activation with human a-thrombin. Blood Coagul Fibrinolysis 1996;7:615-24.
8. Zhang X, Xie Y, Nasjletti A, Xu X, Wolin MS, Hintze TH. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation 1997;95:176-82.
9. Mori K, Takesuchi S, Moritoki H, et al. Endothelium-dependent relaxation of rat thoracic aorta by amrinone-induced nitric oxide release. Eur Heart J 1996;17:308-16.
10. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998;97:576-80.
11. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-71.
12. Delanyi JA, Nossuli TO, Scalia R, Thomas G, Garvey DS, Lefer AM. S-Nitrosylated tissue-type plasminogen activator protects against myocardial ischemia/reperfusion injury in cats: role of the endothelium. J Pharmacol Exp Ther 1996;279:1174-80.
13. Collins P, Rosano GM, Sarrel PM, et al. 17 Beta-estradiol attentuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24-30.
14. Yokokawa K, Tahara H, Kohno M, Mandal AK, Yanagisawa M, Takeda T. Heparin regulates endothelin production through endothelium-derived nitric-oxide in human endothelial-cells. J Clin Invest 1993;92:2080-85.
15. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 1994;94:1172-79.
16. Guo JP, Murohara T, Buerke M, Scalia R, Lefer AM. Direct measurement of nitric oxide released from vascular endothelial cells. J Appl Physiol 1996;81:774-9.
17. Feelisch M, Keim M. Biotransformation of organic nirtates to nitric oxide by vascular smooth muscle and endothelial cells. Biochem Biophy Res Commun 1991;180:286-93.
18. Jay MT, Chirico S, Siow RCM, et al. Modulation of vascular tone by low-density lipoproteins: effects on L-arginine transport and nitric oxide synthesis. Exp Physiol 1997;82:349-60.
19. Pritchard KA Jr, Groszek L, Smalley DM, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995;77:510-8.
20. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992;95:187-94.
21. Boger RH, Bodeboger SM, Mugge A, et al. Supplementation of hypercholesterolemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Artherosclerosis 1995;117:273-84.
22. Ma L, Morita I, Murota S. Enhancement of migration activity in cholesterol-poor endothelial cells by pre-treating with HMG-CoA reductase inhibitors. Biochem Biophys Res Commun 1994;203:1355-61.
23. van Vliet A, Christa G, van Thiel F, et al. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim Biophys Acta 1995;1254:105-11.
24. Lauf U, La Fata V, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997;272:31725-9.
25. Muramatsu J, Kobayashi A, Hasegawa N, Yokouchi S. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin. Atherosclerosis 1997;130:179-82.
26. Wolf A, Zalpour C, Theilmeier G, et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997;29:479-85.
27. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amiodipine Cardiovascular Events Rendomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
28. Califf RM, Granger CB. Hypertension and diabetes and the Fosinopril versus Amiodipine Cardiovascular Events Trial (FACET): more ammunition against surrogate end points. Diabetes Care 1998;21:655-7.
29. Wierzkicki AS, Lumb PJ, Semra YK, Crook MA. Effect of atorvastatin on plasma fibrinogen. Lancet 1998;351:569-70.
30. Vanheel B, Van de Voorde J, Leusen I. Contribution of nitric oxide to the endothelium-dependent hyperpolarization in rat aorta. J Physiol 1994;475:277-84.
31. Oldham CD, Li C, Feng J, et al. Amidative peptide processing and vascular function. Am J Physiol 1997;273:C1908-14.
32. Pedersen TR, Olsson AG, Færgeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-60.
33. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-45.
34. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998;97:1446-52.
35. Abou-Mohamed G, Kaesemeyer WH, Papapetropoulos A, Catravas JD, Caldwell RW. Nitroglycerin (NTG) but not sodium nitroprusside (SNP) increases aortic ring cGMP levels via an L-arginine dependent and L-NAME sensitive pathway [abstract]. J Am Coll Cardiol 1996;27:105A.
36. Abou-Mohamed G, Kaesemeyer WH, Papapetropoulos A, Catravas JD, Caldwell RW. L-arginine in the development and reversal of tolerance to nitroglycerin [abstract]. Int J Microcirc 1996;16:187.
37. Kaesemeyer WH, Abou-Mohamed G, Crute TD, Caldwell RW. Nitrates supplemented with L-arginine for the reversal and treatment of nitrate tolerance: two case reports. Appl Cardiopulmon Pathophys 1997;6:255-62.